YLYingjuan Liu

Yingjuan Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yingjuan Liu has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Inhibition of calpain-mediated HMGB1 alleviates cardiac inflammation and dysfunction induced by ultra-processed foods

    by Claire Ross, Sanskruti Ravindra Gare, Nasser H.O. Alatawi, Oveena Fonseka, Xinyi Chen, Jiayan Zhang, Yihua Han, Andrea Ruiz-Velasco, Riham R.E. Abouleisa, Yingjuan Liu, et al.

    Increased consumption of ultra-processed foods (UPFs) is a risk factor for metabolic disorder–associated heart failure (HF). Here, we demonstrate that UPF-induced calpain-1 aggravated oxidative stress, thereby increasing high mobility group box 1–mediated (HMGB1-mediated) myocardial inflammation, which contributes to cardiac dysfunction. After illustrating the dysregulated inflammatory pathways in human and murine hearts upon metabolic stress, we revealed an increase in calpain-1 alongside profound oxidative stress and inflammation in the failing myocardium. Mechanistically, in neonatal rat cardiomyocytes and human induced pluripotent stem cell–derived cardiomyocytes, HMGB1 was upregulated by calpain-1 and reactive oxygen species (ROS) upon stress of saturated and trans fatty acids. Consequently, HMGB1 promoted a proinflammatory response in macrophages. In contrast, inhibition of calpain or ROS efficiently repressed HMGB1 in cardiomyocytes. Therapeutically, either recombinant adeno-associated virus 9–delivered inhibitor of calpain-1 or its pharmacological inhibitor attenuated ROS and HMGB1-induced inflammation in the myocardium and mitigated HF in both male and female mice fed with an ultra-processed diet. Collectively, we have demonstrated the effects of suppressing calpain-1 and oxidative stress on alleviating myocardial inflammation via blockage of HMGB1 and cardiac dysfunction. The results provide a promising therapeutic strategy for preventing or treating HF in metabolic disorders.

  • Open Access

    Human Cardiac Organoids: Quantification and Qualification in Cardiovascular Studies

    by Yingjuan Liu, Sabu Abraham, Honglin Xu

    Review Yingjuan Liu, Sabu Abraham, and Honglin Xu * Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester M13 9PT, UK. * Correspondence: honglin.xu@postgrad.manchester.ac.uk Received: 4 April 2024; Revised: 29 May 2024; Accepted: 29 May 2024; Published: 29 August 2024 Abstract: The human cardiac organoids (hCOs) represent a three-dimensional (3D) tissue model that mirrors in vivo cardiac conditions. Recent advancements underscore the immense potential of hCOs in several areas including studying early cardiogenesis, modeling heart diseases, screening potential drugs, and even exploring possibilities for cardiac regeneration. Recognizing the pivotal role hCOs play across various applications, this review examines the evolution of key metrics and tools for assessing cardiac organoids tailored for diverse research objectives. Moreover, it deliberates on the limitations of cardiac organoids and outlines the prospective avenues for future research applications of hCOs. Cardiovascular disease (CVD) is the leading cause of morbidity and mortality globally, despite significant research efforts aimed at developing preventive interventions for heart diseases [1]. The reasons for this challenge include the following: (1) the lack of effective therapeutic strategies to help people survive heart attacks; (2) the shortage of reliable models for comprehensive investigations into the mechanisms of human cardiogenesis and maturation; (3) limited resources and techniques for extensive scale of drug screening. Two-dimensional (2D) in vitro models do not precisely mimic the complex in vivo environment that comprises cell-cell and cell-extracellular matrix (ECM) interactions, and regulatory factors [2]. Traditional three-dimensional (3D) cell cultures may fail to recapitulate some morphogenesis and pathological processes due to low genetic and phenotypical heterogeneity [3]. Animal models are currently the gold standards for many assays in modeling human physiological conditions, gene expression patterns and metabolic activities. However, the species distance between animals and humans restricts the direct extrapolation of animal research findings into human heart diseases [4]. 3D cardiac organoid model, which resembles the heart as it contains essential cardiac cell components, structures, and functions, is evolving as an attractive model for basic and pre-clinical CVD research [4]. Cardiac organoids are complex structures that autonomously organize into heart tissues or heart organ-like formations, encompassing a similar ratio of key cardiac cell types like cardiomyocytes (CMs), cardiac fibroblasts (CFs), and endothelial cells (ECs) to the cellular composition of the heart that are cultivated in vitro from embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs) [5,‍6]. Consequently, cardiac organoids can effectively mimic cell-matrix dynamics, cell-cell interactions in human hearts, as well as both physiological and pathological human cardiac development in vivo [7‒9]. The term “cardiac organoid” was initially introduced around two decades before [10], gaining popularity quickly in 2017 [11,‍12]. However, the development and utilization of hCOs have significantly lagged behind other types of organoids such as those of the lung [13], small intestine [14], pancreas [15], liver [16], prostate [17], brain [18], and tumor tissue [19]. The construction of hCOs faces several obstacles associated with the diverse cellular composition and intricate micro-environments [20]. In contrast to 2D cultures, cardiac organoids can replicate 3D morphogenesis and pathological processes in the hearts [8], shedding light on the potential of cardiac organoid as a promising platform for systematic investigations into cardiac self-organization, congenital heart defects, and translational researches. The recently established state-of-art hCO platform resembling the embryonic heart with subcompartments and multiple chamber-like cavities fulfills the specific requirements of drug screening in individual hCOs [21]. The analysis of complex multicellular organoids is becoming feasible due to the evolution of the cutting-edge technologies, including human-induced pluripotent stem cells (hiPSCs), single-cell analysis [22], and multi-photon microscopy. The emergence of optimized iPSCs and cardiac differentiation protocols has accelerated the construction of cardiac organoids in vitro [23]. In this review, we will present recent significant advances in the realm of cardiac organoids and their diverse applications. The various methods of assessing essential functions and features of cardiac organoid are also discussed. Finally, strategies for overcoming existing challenges and future directions are discussed. The heart is the first functional organ developed in human embryos, composed of multiple cell types and regulated by highly hierarchized signaling pathways. CMs contribute 70–85% to the heart by volume but only represent 25–35% of the heart cell populations [24,25]. Non-CM cells, including vascular endothelial cells, vascular smooth muscle cells, CFs, neurons, and immune cells, constitute 65–75% of the total cell population in the heart [26]. Surrounding the cardiac cells and vessels, 3D extracellular matrix (ECM), containing laminin proteins, fibronectin, interstitial collagen, cytokines, growth factors, proteases, and glycoproteins, constitutes the micro-environment to support cells in anisotropic alignment, biochemical signaling, and mechanical strength [27]. There is no globally agreed definition for hCOs, but a typical hCO should be a 3D structure containing major heart cell types and recapitulating the critical heart structures and function [28]. An ideal hCO can model the complex in vivo cardiac microenvironment under both physiological and pathological conditions. The names of “organoid” and “spheroid” are frequently used interchangeably, in certain cases, the 3D heart constructs with scaffolds are also called hCOs. Therefore, we classify the hCOs into two categories: (1) the engineered heart tissue (EHT) and (2) self-assembling cardiac organoids (Figure 1). Figure 1. Classification of human cardiac organoids. The objective of in vitro EHT is to create systems that simulate the physiological structure and function of an in vivo heart. The EHTs are primarily produced by integration of engineering methods and biomaterials rather than natural cardiac developmental mechanisms [28]. Thus, one of the advantages of EHT is that various cardiac cell types derived from stem cells can be co-cultured and introduced onto scaffolds, biomaterials, extracellular matrix (ECM), or bioengineered devices to mold the desired three-dimensional (3D) structure for specific cardiac physiological tests, such as contraction and electrophysiology. The first reported EHTs were simply constructed by fostering intercellular adhesion of co-cultured one or two types of heart cells from rats and mice to form a loose spherical structure referred to as a cardiac spheroid [10,29]. The first creation of functional human EHT using iPSCs was reported later, which involved generating 3D cardiac tissue from these stem cells. This technique has enabled the study of human heart disease and the testing of potential therapies in a more physiologically relevant context [30]. EHTs serve as ideal models for analyzing cardiac contractility and electrophysiology as they can simulate certain aspects of adult cardiac tissue, however, they do not fully replicate the intricate morphology and early developmental patterns observed in natural hearts and lack cell type diversity. Additionally, the construction of EHTs is complex, requiring specialized equipment, making it expensive and challenging to be applied for high-throughput screening. Self-assembling cardiac organoids are cell aggregates that form heart-like structures with minimal external intervention. Congenital heart diseases are the most prevalent type of birth defects. Self-assembling cardiac organoids closely represent the developmental and spatiotemporal patterns of the embryonic heart, facilitating our understanding of early cardiogenesis [31]. Silva et al. constructed an organoid model using multiple lineages derived from human iPSCs to mimic the cellular and structural complexity during early embryogenesis, from which they discovered that the endoderm tissue (gut/intestine) in the organoids promoted the development of cardiac-like tissues, such as an internal CM core and epithelial-like structures [32]. However, this model is not fit for the investigation of the cardiac morphogenesis, as the accelerated development of primitive cystic structures inhibit the cardiac morphogenesis. While multi-lineage embryonic organoids offer advantages for studying the co-development of the foregut and heart, their limitations restrict their application in cardiac-specific physiological function investigations. These limitations include the absence of mature cardiac structures like ventricles and vessels, as well as the presence of additional non-cardiac cell types. To address the specific needs of cardiac research, scientists have developed lineage-specific cardiac organoids. These organoids consist exclusively of heart-relevant cell types, mimicking the structure and function of the human heart more closely. Unlike embryonic organoids, lineage-specific cardiac organoids reserve their capability of continuous cell specification and structural transformations in vitro, resembling in vivo hearts better [33]. In 2021, a self-assembled lineage-specific hCO model named ‘Cardioids’ was reported. The model comprised signaling pathway factors that modulate the CM and endothelium separation, which endowed the cardioids chamber-like structures with cavities. These cardioids show distinct myocardial and endothelial layers interacting with epicardium, resembling early cardiac chamber development. Meanwhile, the critical WNT-BMP signaling pathway in mesoderm and its downstream target HAND1, a transcription factor associated with congenital heart septal defects, was identified to govern the self-organizing of cardioid [8]. In general, lineage-specific cardiac organoids offer a powerful platform for investigating the mechanisms of human cardiogenesis, endothelial and epicardial morphogenesis processes, and modelling of congenital heart diseases. As a newly evolved model for hearts, a guideline on the exanimation and evaluation of the hCOs should be developed to widen their application in either basic or preclinical investigations. To establish a guideline for assessing the hCO quantifications and qualifications, we summarize the available characterization methods for hCOs in terms of morphology, electrophysiology, metabolism, and gene expressions (Figure 2). Figure 2. Guideline for human cardiac organoids evaluations [34‒45]. The shape, size, surface and interior structures of an organoid, cell composition and viability, motions and contractions are all critical morphological parameters to evaluate in organoid studies [46]. Microscopy is the fundamental strategy examining the morphological indicators of an organoid. Surface observations can be achieved by using traditional white balanced or fluorescence microscopy on quantifying the organoids’ sizes, shapes, as well as the process of cell aggregation. However, in contrast to 2D cell cultures, the compacted organoid tissue texture increases the challenges in observing the interior morphological features inside cardiac organoids. Therefore, advanced imaging techniques, like the confocal, light-sheet and multi-photon microscopy, need to be applied to observe alive or crosslinked hCOs. Due to photon scattering caused by dense structure of hCOs, confocal microscopy is limited in viewing the internal structures of thick organoid tissues [47]. One limitation to live imaging of hCOs is the extended scan time caused by pronounced light scattering. This scattering prevents researchers from capturing the inner core regions of cardiac organoids within a single heartbeat. Future advancements in imaging techniques are needed to overcome this challenge [48]. Light-sheet microscopy, characterized by a relatively shorter point scanning time is an alternative in imaging hCOs, but it is constrained by the penetration depth of 3 μm into cardiac organoids due to scattering. To solve this problem, Richards and colleagues combined light-sheet microscopy with a customized two-photon microscopy to achieve reduced scattering due to longer wavelength in scanning deeper regions of hCOs. This approach successfully captured calcium transient profiles in live cardiac organoids [49]. Recently, Ming and colleagues successfully observed the internal structures of cardiac organoids longitudinally using optical coherence tomography without sectioning or staining [49]. To evaluate the morphology of crosslinked hCOs, tissue fixation and sectioning is adopted as it allows extended scan times and higher spatial resolution of imaging. However, hCOs can be nearly invisible after embedding in paraffin or optimal cutting temperature compounds (OCT) due to small sizes and colorlessness [8]. Therefore, the use of tissue clearing reagents or strategies may improve the imaging quality of hCOs with high spatial resolution by enhancing their tissue transparency [46]. However, clearing may cause deformations to the hCOs, therefore, the choice of a clearing method should be carefully chosen based on the morphological parameters of interest within the organoid [50]. For cardiac organoids, contraction is a key morphological parameter to be examined. The measurement of contractile force of EHTs is in real-time and directly quantified, through two elastic posts posited at both sides of hCOs. In contrast, the easiest and cost-effective method of quantifying the contractions of cardiac organoids is the application of motion mapping and analysis of video captured by microscopes [51]. These analyses provide necessary information on contraction rate, duration, magnitude and regularity. Of note, interference from changes in position and orientation due to the robust beating of hCOs required extra consideration to avoid miscalculations. The electrophysiology of cardiomyocytes is an irreplaceable parameter for gaining insights into cardiac function, mechanisms of diseases, and the development of potential therapeutic interventions [52]. In animal studies and monolayer cultures, patch-clamp and multielectrode array (MEA) techniques are used for electrophysiological characterization of CMs. Patch-clamp is a powerful and wide applied method, it records quantitative action potentials and relevant ionic currents at a single-cell level; however, it is not efficient for high throughput projects [53,54]. In contrast, MEA detects action potential propagation and extracellular field potential and can be applied to multiple wells simultaneously, making it more suitable for high throughput investigations [54]. However, the current patch-clamp and MEA assays are mainly designed to assess 2D cultures, it is still a challenge to quantify the action potential of 3D hCOs. One optional method of assessing the action potential of hCOs is to dissociate the organoids into single cells and perform patch-clamp on the cells seeded on glass coverslips. Although this approach facilitates the detection of chamber-specific action potential, the readout may vary from the original electrophysiological features in hCOs after dissociation and culturing on 2D glass coverslips. Additionally, conventional MEAs only record the outer edges of hCOs due to the planar electrodes. Current improvements of MEAs include the design of bendable thin-film MEAs to fully cover the hCOs and 3D MEAs using mesh nanoelectronics or stretchable arrays [55]. Mesh electrodes embedded uniformly in hCOs enable synchronously record of electrophysiology across the whole structure, but we note that the insertion of these mesh electrodes into hCOs may interfere with the development of hCOs, which is especially obvious in long-term studies [56]. The detection of calcium current is important in studying hCOs’ electrophysiology, and to fulfill this, calcium imaging based on fluorescent indicators is employed [7]. For example, Archon1, a recently developed genetically encoded voltage indicators, allows simultaneous detection of changes of calcium concentration across multiple cells induced by action potential within hCOs [7]. However, calcium imaging has limited capability in capture dynamic membrane voltage or specific physiological and pathological action potential waveforms individually [57]. Voltage-sensitive dye was specifically designed to solve this problem, and its intensity changes based on alterations of membrane potential. By this characteristic, the presence of ventricular- and atrial-like regions was identified by distinct action potential durations (APDs) in hCOs [58]. Nevertheless, like the mesh electrodes, the dye-mediated cytotoxicity limits its application in long-term study and need further improvements. Since the heart’s function relies on converting chemical energy into mechanical energy, a well-developed metabolism is critical for the successful application of hCOs. Research suggests that hiPSC differentiation into CMs and subsequent self-organization of hCOs are accompanied by a metabolic shift from anaerobic glycolysis to mitochondrial respiration [59]. Measuring concentrations or metabolic fluxes of metabolites involved in metabolic reactions is a well-established approach for evaluating hCOs’ metabolism [60]. The readouts offer valuable insights into the activation or inhibition of specific metabolic pathways as well as changes in the energy demand of hCOs under physiological or pathological conditions. Specifically, oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) are two robust indicators of metabolic fluxes. The OCR is an indicator of mitochondrial respiration while ECAR indicates proton excretion through glycolysis. Fluctuations in OCR and ECAR are tightly associated with the ATP turnover, and can reflect the metabolism status of hCOs [61]. Of note, multiple types of cells contained in hCOs can interfere with the interpretation of OCR and ECAR caused by the distinct metabolic baseline of each cell-type. Moreover, mitochondrial staining is emerging an effective method of evaluating hCOs’ metabolism which assesses the mitochondrial properties and functions [62]. Gene expression is another crucial indicator for characterizing the phenotypes of hCOs. Quantitative RT-qPCR of gene markers was utilized to compare 2D cardiomyocytes and hCOs at different time points (Day 14 and Day 21). It was observed that hCOs provide a microenvironment that sustains the various cardiovascular cell types [63]. However, it is difficult to quantify the expression of genes in hCOs. For example, multi-omic analysis of hCOs proteomics can reveal the activity and abundance of a particular protein, as well as its post-translational modifications [64]. Given the diverse cell types within hCOs, most researchers prefer single-cell sequencing (scRNA-seq) to analyzing the bulk population to obtain comprehensive information about the cell’s composition, metabolism, and differentiation trajectories. Notably, scRNA-seq can detect low-abundance cell types but offers lower sequencing depth and coverage compared to bulk sequencing. Of note, single-cell dissociation for sequencing resulted in the loss of spatial information. To overcome this problem, spatial transcriptomics has been introduced owing to its ability to identify cellular differentiation...


  • Open Access

    Atrial Septal Defect (ASD) associated long non-coding RNA STX18-AS1 maintains time-course of in vitro cardiomyocyte differentiation

    by Yingjuan Liu, Mun-Kit Choy, Sabu Abraham, Gennadiy Tenin, Graeme C. Black, Bernard D. Keavney


  • Open Access

    Progress of 3D Organoid Technology for Preclinical Investigations: Towards Human In Vitro Models

    by Yingjuan Liu, Honglin Xu, Sabu Abraham, Xin Wang, Bernard D. Keavney

    Review Progress of 3D Organoid Technology for Preclinical Investigations: Towards Human In Vitro Models Yingjuan Liu *, Honglin Xu, Sabu Abraham, Xin Wang, and Bernard D. Keavney* Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, University of Manchester, M13 9PT, UK. * Correspondence: yingjuan.liu@manchester.ac.uk (Yingjuan Liu); bernard.keavney@manchester.ac.uk (Bernard D. Keavney) Received: 1 November 2022 Accepted: 24 November 2022 Published: 21 December 2022 Currently, with an increased requirement for new therapeutic strategies, preclinical drug testing or screening platforms have rapidly evolved in recent years. In comparison to traditional 2D cell cultures, 3D organoids or spheroids with or without scaffolds improve the microenvironment of in vitro cultures, advancing the in vitro biological observation and enabling mechanistic studies of drug reactions in the human tissue-like environment. 3D organoids and spheroids are straightforward to produce, and relatively uniform in size and shape. This helps to facilitate high throughput screening requirements. Spheroids and organoids have been applied in anti-cancer drug testing, toxicity evaluations, as well as mechanism studies for variable organ systems, including the intestine, liver, pancreas, brain, and heart. Among 3D cultures of spheroids and organoids, ‘tumour spheroids’ formed by dissociated tumour tissues or cancer cell lines are relatively simple in composition and commonly applied to anticancer drug screening. The ‘healthy organoids’ differentiated from hiPSCs/hESCs are more complex in cell composition, distribution, structure and function with higher similarity to in vivo organs, and have found applications in toxicity tests, personalised medicine, and therapeutic and mechanistic studies. In most cases, the multicellular 3D organoids are more resistant and stable in reaction to stimulations or chemicals in vitro , suggesting more accurate modelling of in vivo responses. Here, we review recent progress in human-origin organoid/spheroid systems and their applications in preclinical studies.


  • Open Access

    Data on cardiac lncRNA STX18-AS1 expression in developing human hearts and function during in vitro hESC-cardiomyocyte differentiation

    by Yingjuan Liu, Mun-Kit Choy, Sabu Abraham, Gennadiy Tenin, Graeme C. Black, Bernard D. Keavney


  • Open Access

    STX18-AS1 is a Long Noncoding RNA predisposing to Atrial Septal Defect via downregulation of NKX2-5 in differentiating cardiomyocytes

    by Yingjuan Liu, Mun-Kit Choy, Sabu Abraham, Gennadiy Tenin, Graeme C. Black, Bernard D. Keavney

    Previous genome-wide association studies (GWAS) have identified a region of chromosome 4p16 associated with the risk of Atrial Septal Defect (ASD), which is among the commonest Congenital Heart Disease (CHD) phenotypes. Here, we identify the responsible gene in the region and elucidate disease mechanisms. Linkage disequilibrium in the region, eQTL analyses in human atrial tissues, and spatio-temporal gene expression studies in human embryonic hearts concordantly suggested the long noncoding RNA (lncRNA) STX18-AS1 as the causative gene in the region. Using CRISPR/Cas9 knockdown in HepG2 cells, STX18-AS1 was shown to regulate the expression of the key cardiac transcription factor NKX2-5 via a trans- acting effect on promoter histone methylation. Furthermore, STX18-AS1 knockdown depleted the potential of human embryonic stem cells (H9) to differentiate into cardiomyocytes, without affecting their viability and pluripotency, providing a mechanistic explanation for the clinical association.

  • Top Cited Papers
    Open Access

    Global birth prevalence of congenital heart defects 1970–2017: updated systematic review and meta-analysis of 260 studies

    by Yingjuan Liu, Sen Chen, Liesl Zühlke, Graeme C Black, Mun-Kit Choy, Ningxiu Li, Bernard D Keavney

    Globally, access to healthcare and diagnostic technologies are known to substantially impact the reported birth prevalence of congenital heart disease (CHD). Previous studies have shown marked heterogeneity between different regions, with a suggestion that CHD prevalence is rising globally, but the degree to which this reflects differences due to environmental or genetic risk factors, as opposed to improved detection, is uncertain. We performed an updated systematic review to address these issues. Studies reporting the birth prevalence of CHD between the years 1970–2017 were identified from searches of PubMed, EMBASE, Web of Science and Google Scholar. Data on the prevalence of total CHD and 27 anatomical subtypes of CHD were collected. Data were combined using random-effect models. Subgroup and meta-regression analyses were conducted, focused on geographical regions and levels of national income. Two hundred and sixty studies met the inclusion criteria, encompassing 130 758 851 live births. The birth prevalence of CHD from 1970–2017 progressively increased to a maximum in the period 2010–17 of 9.410/1000 [95% CI (confidence interval) 8.602–10.253]. This represented a significant increase over the fifteen prior years (P = 0.031). The change in prevalence of mild CHD lesions (ventricular septal defect, atrial septal defect and patent ductus arteriosus) together explained 93.4% of the increased overall prevalence, consistent with a major role of improved postnatal detection of less severe lesions. In contrast the prevalence of lesions grouped together as left ventricular outflow tract obstruction (which includes hypoplastic left heart syndrome) decreased from 0.689/1000 (95% CI 0.607–0.776) in 1995–99, to 0.475/1000 (95% CI 0.392–0.565; P = 0.004) in 2010–17, which would be consistent with improved prenatal detection and consequent termination of pregnancy when these very severe lesions are discovered. There was marked heterogeneity among geographical regions, with Africa reporting the lowest prevalence [2.315/1000 (95% CI 0.429–5.696)] and Asia the highest [9.342/1000 (95% CI 8.072–10.704)]. The reported prevalence of CHD globally continues to increase, with evidence of severe unmet diagnostic need in Africa. The recent prevalence of CHD in Asia for the first time appears higher than in Europe and America, where disease ascertainment is likely to be near-complete, suggesting higher genetic or environmental susceptibility to CHD among Asian people.


  • BARIATRIC SURGERY ENHANCES REVERSE CHOLESTEROL TRANSPORT AND HIGH DENSITY LIPOPROTEIN FUNCTIONALITY

    by J.H. Ho, S. Adam, T. Siahmansur, Y. Liu, S. Azmi, R. Aghamohammadzadeh, K. Siddals, R.A. Malik, A.A. Syed, B.J. Ammori, et al.


  • Open Access

    Promoter interactome of human embryonic stem cell-derived cardiomyocytes connects GWAS regions to cardiac gene networks

    by Mun-Kit Choy, Biola M. Javierre, Simon G. Williams, Stephanie L. Baross, Yingjuan Liu, Steven W. Wingett, Artur Akbarov, Chris Wallace, Paula Freire-Pritchett, Peter J. Rugg-Gunn, et al.

    Long-range chromosomal interactions bring distal regulatory elements and promoters together to regulate gene expression in biological processes. By performing promoter capture Hi-C (PCHi-C) on human embryonic stem cell-derived cardiomyocytes (hESC-CMs), we show that such promoter interactions are a key mechanism by which enhancers contact their target genes after hESC-CM differentiation from hESCs. We also show that the promoter interactome of hESC-CMs is associated with expression quantitative trait loci (eQTLs) in cardiac left ventricular tissue; captures the dynamic process of genome reorganisation after hESC-CM differentiation; overlaps genome-wide association study (GWAS) regions associated with heart rate; and identifies new candidate genes in such regions. These findings indicate that regulatory elements in hESC-CMs identified by our approach control gene expression involved in ventricular conduction and rhythm of the heart. The study of promoter interactions in other hESC-derived cell types may be of utility in functional investigation of GWAS-associated regions.